explore -WSS

explore

author：entertainment 2025-09-06 02:03:18 - browse：73

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Parkland mass shooting to be reenacted for lawsuit

leisure time

WSS

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Slain Parkland victim's father speaks out following reenactment

Why don't Americans have at

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Study gives hint on South Asians’ higher risk of cardiovascular disease

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bernie Sanders gets little from pharma CEOs on drug prices

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AMAs digital advisors table RPM coding reform proposal, again

Medical records are filled with copy

STAT Boddities: What happens to the brain when we get scared?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Malaria cases in Florida and Texas: Here’s what you need to know

Eli Lilly reports tirzepatide MASH success during Q4 earnings

hotspot

Why Eli Lilly’s earnings didn’t quite live up to the hype

Ebola vaccine can save some who are already sick, per new study

Russian court extends detention of American musician

Congress might make insulin pumps more accessible to the blind

Websites selling Wegovy, Zepbound ingredients targeted by FDA

New company forms to vet health AI models, root out weaknesses

Wikipedia

leisure time

hotspot

focus